Development of novel agents and combinations for renal carcinoma

Matthew D. Galsky, Guru Sonpavde, Ranjit Kapil, Mark T. Fleming, G. Varuni Kondagunta, Thomas E. Hutson, Cora Sternberg

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Based on a better understanding of the pathogenesis of renal carcinoma, the last 5 years has witnessed a rapid transition of novel agents from the bench to the bedside. Multiple new drugs have already been approved for standard use including sunitinib, sorafenib, and temsirolimus with additional agents including everolimus, bevacizumab, and pazopanib under review by the regulatory agencies. This review will highlight the clinical data, which support the use of these novel agents and highlight current approaches exploring combination therapy.

Original languageEnglish
Pages (from-to)97-103
Number of pages7
JournalUpdate on Cancer Therapeutics
Issue number2
StatePublished - Dec 2008
Externally publishedYes


  • Metastatic
  • Renal carcinoma
  • Targeted therapy


Dive into the research topics of 'Development of novel agents and combinations for renal carcinoma'. Together they form a unique fingerprint.

Cite this